Gensaic

Gensaic is an early-stage biotech leveraging a proprietary platform, FORGE™, to discover and design novel protein-based delivery systems for metabolic diseases. The company has gained significant validation through a major collaboration with Novo Nordisk, with a potential value of up to $354 million per target. With a strong founding team and experienced board, Gensaic is positioned at the intersection of AI-driven protein design and the high-demand field of metabolic therapeutics, though its technology remains in the pre-clinical discovery phase.

FORGE™ (Functional Optimization by Recursive Genetic Evolution) platform combining billion-scale unbiased protein screening for novel delivery mechanisms with AI-guided generative protein design to create multi-functional, tissue-selective intracellular delivery vehicles.

Gensaic competes in the crowded and rapidly evolving field of AI-driven drug discovery and targeted delivery, facing companies like Generate:Biomedicines, Absci, and large biopharma internal efforts. Its differentiation lies in its specific focus on unbiased discovery of novel delivery mechanisms combined with generative design, all applied to the high-value metabolic disease space.